The results also show a decrease in antibiotic use, hospital length of stay, and overall cost to the patient.

New research was found on alcohol consumption as a modifiable risk factor in dementia, in a study out of South Korea.

The treatment is a novel, investigational anti-C5 recycling monoclonal antibody showing promise for treating patients with paroxysmal nocturnal hemoglobinuria.

Leveraging data from the Tromsø study, the D2d study, and the DPVD study, a systematic review and meta-analysis concluded vitamin D supplementation could help reduce risk of progression to diabetes by 15% among people with prediabetes.

Thus far, the phase 2 data on CP101 was generally positive for the treatment of recurrent C difficile infections.

A new-user comparator study of adults with type 2 diabetes indicates use of SGLT2 inhibitors was associated with a 54% lower risk of hospitalizations for heart failure and a 15% lower risk of a modified MACE outcome compared to use of DPP-4 inhibitors.

An interview with Victoria Barrio, MD, and Fabiana Castro Porto Silva Lopes, MD, about the Society for Pediatric Dermatology and its efforts to address diversity in the dermatology field.

An analysis of the Lifelines cohort revealed DED had a significant impact on work functioning, comparable to the impact of other chronic diseases considered function impairing.

Musculoskeletal ultrasound evaluated tophus size and double contour sign in lower extremity joints of patients with gout before and after initiating uric acid lowering therapy.

It wasn't the unavailability of varenicline, but the inaccessibility, that perpetuated the reduced prevalence of prescriptions. Investigators speculated that patient, clinician awareness and concerns related to nitrosamine were contributing factors.

Teresa Quattrin, MD, leads a discussion on the benefits of using medications for type 2 diabetes to manage patients who have type 1 diabetes.

Kimberly Simmons, MD, MPH/MSPH, reviews ADA guidelines recommendations for the management of type 1 diabetes.

Phase 2b findings suggest VEGF-C/D inhibition with 2.0 mg OPT-302 in combination with ranibizumab achieves superior vision gains compared to the current standard of care for nAMD.

The DECT scoring system obtained excellent diagnostic performance for differentiating early-stage gout from middle-stage gout, with sensitivity, positive and negative predictive values, and specificity all achieving an accuracy of > 85%.

Drs Diana Isaacs and Natalie Bellini highlight the need for improved screening, greater awareness of clinical trial opportunities, and clinician education to improve early diagnosis and outcomes for people with T1D.

Sumita Singh, a T1D advocate, discusses with Diana Isaacs and Natalie Bellini how teplizumab and other advances are providing hope to the T1D community and talks about the challenges and needs of a diverse T1D patient population.

Sumita Singh, a T1D advocate, discusses her family’s decision to enroll their daughter Bella in a clinical trial for T1D and shares their experience.

Sumita Singh shares about her daughter Bella’s type 1 diabetes (T1D) diagnosis and how their family navigated the logistical and emotional challenges of receiving a T1D diagnosis.

A recent study highlighted new information on racial disparities in health care for Black and Hispanic pediatric patients with atopic dermatitis.

The rare condition can lead to life-threatening anemia in the fetus and currently lacks FDA-approved treatments.

Singh presented during the recent APSARD conference. onthe topic of ADHD and bipolar disorder.

An analysis of more than a dozen cohort studies containing data from more than 30,000 offspring provides clinicians with the most detailed overview yet of differences in cardiometabolic health outcomes in those conceived naturally compared to those conceived with use of assisted reproductive technologies.

New research into egg, peanut allergies and sensitization raised questions about allergy incidence rates and early exposure.

An analysis of data from the Rochester Epidemiology Project suggests those with breast cancer or lymphoma who received treatment with anthracycline therapy experienced a more than doubling in risk of heart failure compared to controls without cancer.

Amid a blood shortage and continued stigmatization of HIV risk, it's hard to feel good about the FDA's delayed decision—though good may still come of it.